These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 37090741)

  • 1. Targeting immune checkpoints in anti-neutrophil cytoplasmic antibodies associated vasculitis: the potential therapeutic targets in the future.
    Pan M; Zhao H; Jin R; Leung PSC; Shuai Z
    Front Immunol; 2023; 14():1156212. PubMed ID: 37090741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The clinical significance of circulating follicular helper T cells in patients with anti-neutrophil cytoplasmic myeloperoxidase antibody-associated vasculitis].
    Wang S; Zheng MJ; Zhou XL; Liu YQ; Shuai ZW
    Zhonghua Nei Ke Za Zhi; 2018 Oct; 57(10):738-742. PubMed ID: 30293334
    [No Abstract]   [Full Text] [Related]  

  • 3. Association between Loss of Immune Checkpoint Programmed Cell Death Protein 1 and Active ANCA-Associated Renal Vasculitis.
    Hakroush S; Tampe B
    Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Next generation of anti-immune checkpoints antibodies].
    Bonnefoy N; Olive D; Vanhove B
    Med Sci (Paris); 2019 Dec; 35(12):966-974. PubMed ID: 31903901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Co-inhibitor BTLA Is Functional in ANCA-Associated Vasculitis and Suppresses Th17 Cells.
    Werner K; Dolff S; Dai Y; Ma X; Brinkhoff A; Korth J; Gäckler A; Rohn H; Sun M; Cohen Tervaert JW; van Paassen P; Kribben A; Witzke O; Wilde B
    Front Immunol; 2019; 10():2843. PubMed ID: 31921121
    [No Abstract]   [Full Text] [Related]  

  • 6. Immune checkpoint inhibitors: breakthroughs in cancer treatment.
    Kong X; Zhang J; Chen S; Wang X; Xi Q; Shen H; Zhang R
    Cancer Biol Med; 2024 May; 21(6):451-72. PubMed ID: 38801082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Insights Into Novel Immune Checkpoint Inhibitors.
    Lee JB; Ha SJ; Kim HR
    Front Pharmacol; 2021; 12():681320. PubMed ID: 34025438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble immune checkpoint molecules in patients with antineutrophil cytoplasmic antibody-associated vasculitis.
    Pyo JY; Yoon T; Ahn SS; Song JJ; Park YB; Lee SW
    Sci Rep; 2022 Dec; 12(1):21319. PubMed ID: 36494415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Progress on tumor immune checkpoints and their inhibitors in tumor therapy].
    Wang L; Bai L
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2021 Jul; 37(7):663-670. PubMed ID: 34140079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging Targets of Immunotherapy in Gynecologic Cancer.
    Cheng H; Zong L; Kong Y; Gu Y; Yang J; Xiang Y
    Onco Targets Ther; 2020; 13():11869-11882. PubMed ID: 33239889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.
    Qin S; Xu L; Yi M; Yu S; Wu K; Luo S
    Mol Cancer; 2019 Nov; 18(1):155. PubMed ID: 31690319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoints and cancer development: Therapeutic implications and future directions.
    Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
    Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second- and third-generation drugs for immuno-oncology treatment-The more the better?
    Dempke WCM; Fenchel K; Uciechowski P; Dale SP
    Eur J Cancer; 2017 Mar; 74():55-72. PubMed ID: 28335888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging targets in cancer immunotherapy.
    Burugu S; Dancsok AR; Nielsen TO
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):39-52. PubMed ID: 28987965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated Level of Serum Interleukin-21 and Its Influence on Disease Activity in Anti-Neutrophil Cytoplasmic Antibodies Against Myeloperoxidase-Associated Vasculitis.
    Xu J; Zhao H; Wang S; Zheng M; Shuai Z
    J Interferon Cytokine Res; 2022 Jun; 42(6):290-300. PubMed ID: 35416717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CMTM6-Deficient Monocytes in ANCA-Associated Vasculitis Fail to Present the Immune Checkpoint PD-L1.
    Zeisbrich M; Chevalier N; Sehnert B; Rizzi M; Venhoff N; Thiel J; Voll RE
    Front Immunol; 2021; 12():673912. PubMed ID: 34108971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules.
    D'Arrigo P; Tufano M; Rea A; Vigorito V; Novizio N; Russo S; Romano MF; Romano S
    Curr Med Chem; 2020; 27(15):2402-2448. PubMed ID: 30398102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased Expression of Negative Immune Checkpoint VISTA by CD4+ T Cells Facilitates T Helper 1, T Helper 17, and T Follicular Helper Lineage Differentiation in GCA.
    Hid Cadena R; Reitsema RD; Huitema MG; van Sleen Y; van der Geest KSM; Heeringa P; Boots AMH; Abdulahad WH; Brouwer E
    Front Immunol; 2019; 10():1638. PubMed ID: 31379838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenesis of ANCA-associated vasculitis: An update.
    Jarrot PA; Kaplanski G
    Autoimmun Rev; 2016 Jul; 15(7):704-13. PubMed ID: 26970490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of anti-glomerular basement membrane antibodies and glomerular neutrophil activation on glomerulonephritis in experimental myeloperoxidase-antineutrophil cytoplasmic antibody vasculitis.
    Kanzaki G; Nagasaka S; Higo S; Kajimoto Y; Kanemitsu T; Aoki M; Nagahama K; Natori Y; Tsuboi N; Yokoo T; Shimizu A
    Nephrol Dial Transplant; 2016 Apr; 31(4):574-85. PubMed ID: 26582929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.